Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

Journal of Clinical Investigation

Volumn 106, Issue 12, 2000, Pages 1489-1499

  Shibata, M ^a   Yamada, S ^a   Ram Kumar, S ^a   Calero, M ^a   Bading, J ^a   Frangione, B ^a   Holtzman, D M ^a   Miller, C A ^a   Strickland, D K ^a   Ghiso, J ^a   Zlokovic, B V ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 1; UNCLASSIFIED DRUG;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; INTERSTITIAL FLUID; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT;

EID: 0034521392     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10498     Document Type: Article

References (72)

1. Biology of Aβ amyloid in Alzheimer's disease
2. Alzheimer's disease: Genotype, phenotype, and treatments
3. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
4. The role of Aβ42 in Alzheimer's disease
5. Alzheimer disease: A model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases
6. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau
7. Amyloid plaque core protein in Alzheimer disease and Down syndrome
8. Differences between vascular and plaque core amyloid in Alzheimer's disease
9. β-amyloid (1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease
10. Amyloid β-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels
11. The length of amyloid-β in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-β 1-42 in Alzheimer's disease
12. Isolation and quantification of soluble Alzheimer's amyloid-β peptide from biological fluids
13. Production of the Alzheimer amyloid-β protein by normal proteolytic processing
14. Characterization of β-amyloid peptide from human cerebrospinal fluid
15. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid
16. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains
17. The cerebrospinal-fluid soluble form of Alzheimer's amyloid-β is complexed to SP-40, 40 (apolipoprotein J), and inhibitor of the complement membrane-attack complex
18. Characterization of apolipoprotein J-Alzheimer's Aβ interaction
19. Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2,E3, and E4 isoforms and to isoforms from human plasma
20. Transthyretin sequesters amyloid β-protein and prevents amyloid formation
21. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
22. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma
23. β2-Macroglobulin as a β-amyloid peptide-binding plasma protein
24. Generation of β-amyloid in the secretory pathway in neuronal and non-neuronal cells
25. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging
26. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
27. High tissue content of soluble amyloid-β 1-40 is linked to cerebral amyloid angiopathy
28. 1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
29. Fate of cerebrospinal fluid-borne amyloid β-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries
30. Clearance of amyloid β-peptide from brain: Transport or metabolism?
31. The molecular and genetic basis of AD: The end of the beginning
32. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
33. 1-40: Asymmetrical binding, endocytosis and transcytosis at the apical side of brain microvascular endothelial cell monolayer
34. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor
35. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid β-protein via a lipoprotein pathway: Implications for cerebral amyloid angiopathy
36. Isoform-specific effect of apolipoprotein E on cell survival and β-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures
37. 2-macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein
38. 2-macroglobulin enhances the clearance of endogenous soluble β-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons
39. Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers
40. Albumin outflow into deep cervical lymph from different regions of rabbit brain
41. Apolipoprotein E and Alzheimer's disease
42. α2-macroglobulin is genetically associated with Alzheimer's disease
43. Effects of aluminum on cerebrospinal fluid secretion
44. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A
45. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein an mediates its degradation
46. Low density lipoprotein receptor-related protein/α 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans
47. Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39 kDa receptor associated protein in embryonic mouse tissues
48. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β-peptide in aged squirrel monkey with cerebral amyloid angiopathy
49. Passage of human amyloid-β protein 1-40 across the murine blood-brain barrier
50. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier
51. Isoform-specific effects of apolipoproteins E2, E3, E4 on cerebral capillary sequestration and blood brain barrier transport of circulating Alzheimer's amyloid β
52. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease
53. 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor
54. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
55. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
56. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
57. ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease
58. Amyloid β-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells
59. β-amyloid mediated vasoactivity and vascular endothelial damage
60. Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme
61. Proteolytic degradation of Alzheimer's disease amyloid β-peptide by a metalloproteinase from microglia cells
62. Blood-brain barrier transport of circulating Alzheimer's amyloid-β
63. 1-40 labels amyloid deposits in the aged primate brain in vivo
64. The putative blood-brain barrier transporter for the β-amyloid binding protein apolipoprotein J is saturated at physiological concentrations
65. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid-β in guinea pigs
66. 140/vector complex
67. Cerebral pericytes: A second line of defense in controlling blood-brain barrier peptide metabolism
68. Comparison of subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin
69. Receptor-associated protein is a folding chaperone for low-density lipoprotein receptor-related protein
70. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β-peptides
71. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease
72. In vivo expression of apolipoprotein E reduces amyloid β deposition in a mouse model of Alzheimer's disease